Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors

Breast cancer patients who are HER2-positive receive targeted inhibitors to HER2, including trastuzumab and lapatinib. While patients benefit from the use of HER2 inhibitors, many fail therapy and almost all patients become resistant to treatment, indicating a critical need to prevent treatment fail...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Elizabeth S., Abt, Melissa A., Hill, Elizabeth G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342830/
https://www.ncbi.nlm.nih.gov/pubmed/25515931
http://dx.doi.org/10.1007/s10549-014-3227-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342830/
https://www.ncbi.nlm.nih.gov/pubmed/25515931
http://dx.doi.org/10.1007/s10549-014-3227-9

Ejemplares similares